Columns for Biopharmaceutical Discovery

Agilent Technologies Inc. introduced the latest updates to its AdvanceBio family of columns. The new AdvanceBio Peptide Mapping BioHPLC and ZORBAX RRHD 300-HILIC columns are designed for the separation, characterization and analysis of a wide range of proteins, monoclonal antibodies, peptides and additional biologics. Each of these columns enables users to achieve the highest-resolution results.

The peptide mapping column for HPLC can rapidly determine the primary protein structure and identify modifications with unparalleled speed and sensitivity. It can produce exceptional analytical results two to three times faster than conventional peptide mapping with fully porous HPLC columns, which can take up to 60 minutes. Each batch of mapping media is tested with a rigorous peptide mix to ensure suitability and reproducibility, enabling the identification of key peptides in complex peptide maps. All available columns are stable to 600-bar, enabling maximum UHPLC instrument performance. They also deliver exceptional performance with legacy 400-bar instruments.

The new HILIC columns are the only sub 2-μm, 300Å HILIC columns available today. They are designed specifically for users seeking faster, higher-resolution separation of peptides, polar glycopeptides, proteins, antibodies, conjugates, new biological entities and biopharmaceuticals. Hydrophilic interaction liquid chromatography is designed to resolve hydrophilic glycopeptide variants. It also provides excellent peak shape for polar glycopeptides that have limited retention and resolution with reversed-phased columns. For 1.8 μm particles, the columns enable rapid analysis and 1200-bar stability with exceptional accuracy. They provide orthogonal and complementary separations to reversed-phase HPLC.

Agilent Technologies Inc., 1-800-227-9770, www.agilent.com.